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Mucolipidosis type IV (MLIV) is an autosomal recessive lysosomal storage disorder characterized by severe psy-
chomotor retardation and ophthalmologic abnormalities, including corneal opacity, retinal degeneration, and stra-
bismus. Unlike the situation in other lysosomal disorders, the accumulation of heterogeneous storage material
observed in MLIV does not result from a block in the catabolic pathways but is due to an ill-defined transport
defect in the late steps of endocytosis. With the aim of cloning the MLIV gene, we searched in the 19p13.2-13.3
region, where the locus previously had been assigned by linkage mapping. In this region, we have identified a novel
gene that is mutated in all patients with MLIV who were enrolled in our study. One patient was homozygous for
the splice-acceptor mutation, and another was homozygous for a deletion removing the first six exons of the gene.
In addition, four compound heterozygotes for these two mutations were identified. Haplotype analysis indicates
that we have identified the two major founder mutations, which account for 195% of MLIV chromosomes in
Ashkenazi Jewish patients. The gene, ML4, encodes a protein named “mucolipidin,” which localizes on the plasma
membrane and, in the carboxy-terminal region, shows homologies to polycystin-2, the product of the polycystic
kidney disease 2 gene (PKD2) and to the family of transient receptor potential Ca2+ channels. Mucolipidin is likely
to play an important role in endocytosis.
Introduction
Mucolipidosis type IV (MLIV [MIM 252650]) is a pro-
gressive neurological disease that usually presents during
the 1st year of life, with mental retardation, corneal
opacities, and delayed motor milestones (Berman et al.
1974; Amir et al. 1987). Marked heterogeneity in the
clinical symptoms has been observed, even among sib-
lings. Patients from 170 families have been described;
190% of them are Ashkenazi Jewish (Raas-Rothschild
et al. 1999). The name “mucolipidosis” derives from the
presence of cytoplasmic inclusions of sphingolipids,
phospholipids, and acid mucopolysaccharides called
“storage bodies,” which are seen (by electron micros-
copy) in almost every cell type of the patients and are
similar to those observed in individuals with mucopoly-
saccharide and lipid-storage disorders (Tellez-Nagel et
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al. 1976; Bargal and Bach 1988, 1997; Folkerth et al.
1995; Goldin et al. 1995). In contrast to what is seen
in most other lipid-storage diseases in which lysosomal
hydrolases or activator proteins are defective, extensive
studies have shown normal activities of all lysosomal
hydrolases participating in the catabolism of the stored
macromolecules in MLIV cells, suggesting an alternative
mechanism for storage in this cell type (Chen et al.
1998).
Further evidence that the catabolic pathways are not
affected in MLIV comes from studies performed with
labeled phosphatidylcholine, one of the major lipid
classes that accumulate in MLIV (Bargal and Bach
1989), studies showing increased retention in the ly-
sosomes of MLIV fibroblasts but normal degradation
(Bargal and Bach 1997). In addition, a substantial al-
teration of the movement of various endocytic markers
along the lysosomal pathway has been demonstrated
in MLIV cells (Chen et al. 1998). Taken together, these
findings indicate that the cellular phenotype observed
in patients with MLIV is likely due to a defect in sort-
ing and/or transport along the late endocytic pathway.
This could explain both the absence of massive ac-
cumulation of material (an accumulation that is seen
in other storage disorders) and the lack of progression
of clinical manifestations of the disease during 2–3
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Figure 1 a, ORF map of ML4 cDNA. Short vertical bars denote possible translation start sites; long bars denote stop codons. The ML4
coding region is gray shaded. The 2,272-bp ML4 transcript contains an ORF of 1,635 bp encoding a protein of 545 amino acids. A 2,037-bp
alternative spliced form, missing a 235-bp region that is denoted by the thick bar, also is shown. Since te size of the spliced region is not an
exact multiple of 3, this alternative ML4 transcript presents a longer ORF (1,740 bp, encoding a 580-amino-acid protein), with the first Met
located at nucleotide position 81. The proteins encoded by the two forms differ in their NH2 portions, whereas they are identical for the last
345 residues, because of the usage of the same reading frame in the two transcripts (the region denoted by the double-arrowheaded line)
downstream of the splicing event. b, Northern blot analysis of the ML4 gene. A cDNA probe spanning the entire coding sequence of ML4 was
hybridized to commercially available northern blot containing 2 mg of poly(A) RNA from various human adult tissues. A band of ∼2.2 kb,
consistent with the size of the cDNA contig, is detected in all tissues tested, with the exception of colon and thymus. Hybridization to a human
b-actin cDNA revealed almost equal amounts of poly(A) RNA in each lane.
decades of life (Chen et al. 1998). The mapping of the
MLIV locus to chromosome 19p13.2-13.3 has been
defined, by linkage analysis, as a 5.62-cM interval be-
tween markers D19S1034 and D19S884 (Slaugen-
haupt et al. 1999). Several markers within the linked
interval display significant linkage disequilibrium with
the disorder. Furthermore, haplotype analysis suggests
that two independent gene mutations account for
195% of MLIV chromosomes in Ashkenazi Jewish pa-
tients (Slaugenhaupt et al. 1999).
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Figure 2 Mutation D6432 in patients with MLIV. a, ML4 gene, which is organized into 13 exons. The unblackened boxes denote the
ML4 exons removed by the D6432 deletion; the blackened boxes denote the exons that are retained. b, D6432 Interstitial deletion removing
6,432 bp of genomic DNA, denoted by the dotted line. The primer pair (i.e., ZFP2F oligonucleotide, designed on the basis of the sequence 2.5
kb upstream of the first base of the ML4 cDNA, and 1296R, designed on the basis of intron 7; see the Patients, Material, and Methods section)
used to amplify the breakpoint is also shown. The electropherogram at the bottom left corresponds to the nucleotide sequence across the
breakpoint as determined in patient GM02525. c, Segregation of the 1.87-kb junction fragment in patients WG909, GM02525, GM02526,
GM02529, and GM02533A (see text) and in the carrier father, WG987. The wild-type allele could not be amplified by PCR, because of its
large size (8.3 kb), as shown in control genomic DNA (lane C).
Patients, Material, and Methods
Patients’ Cell Lines
Fibroblast cell lines were obtained from the Reposi-
tory for Mutant Human Cell Strains, Montreal Chil-
dren’s Hospital (for patients WG0987, WG0988, and
WG0909) and from the Coriell Cell Repositories, Cam-
den, NJ (for patients GM02525, GM02526, GM02527,
and GM02529). For patient GM02533A, we purchased
genomic DNA only.
ML4 cDNA cloning
Expressed Sequence Tags database (Boguski et al.
1993) searches were performed as described elsewhere
(Banfi et al. 1998). Selected cDNA clones (IMAGE
clones 209402, 21977, and 2517653) were obtained
from the UK Human Genome Mapping Project Resource
Centre.
DNA Sequencing
Automated sequencing (by an Applied Biosystems
ABI 377 fluorescent sequencer) was performed with
both vector- and gene-specific oligonucleotide primers.
The nucleotide sequence of the human ML4 cDNA has
been submitted to GenBank, under accession number
AJ293659.
Computer Sequence Analysis
BLAST searches using chromosome 19 markers as
queries was performed against both the High Through-
put Genomic Sequences and the Non-Redundant Se-
quences nucleotide databases of the National Center for
Biotechnology Information. Human plasmid artificial
chromosome (PAC) or human bacterial artificial chro-
mosome (BAC) genomic sequences spanning the MLIV
critical region were analyzed by the NIX—Identity Un-
known Nucleic Sequence software available from the
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Figure 3 Mutation 486-2ArG in patients with MLIV. a, Lack of 165 bp, corresponding to exon 4 skipping, observed, at the cDNA level,
by RT-PCR. The electropherogram shows the cDNA sequence across the deletion. The mutated allele encodes a truncated protein that retains
only the first 21 amino acids of the wild-type allele. The region of homology to the PKD2 gene family is deleted in this mutant. b, 486-2ArG
mutation, which segregates with the disease in the family of patient WG909. The electropherograms indicate the genomic sequences surrounding
the 486-2ArG mutation. The mother is a carrier of the mutation, showing heterozygosity at the 486-2 position, whereas the father, who is a
carrier of the D6432 allele, is hemizygous for a portion of the ML4 gene (see fig. 2b and text). The WG909 proband is a compound heterozygote
for the 486-2ArG and D6432 mutations. c, RT-PCR of RNA from fibroblast cell lines, performed with primers located on exons 3 (MC21E)
and 5 (MC21B) (see the Patients, Material, and Methods section). An altered size fragment, of 142 bp (lower arrow), is amplified in patients
WG909, GM02526, GM02527, and GM02529 and in the carrier mother, WG988. The wild-type fragment, of 307 bp (upper arrow), is present
only in the unaffected parents—WG987 and WG988—and in the fibroblast control cDNA sample. A plus sign () and a minus sign () denote,
respectively, the presence and absence of RT in the RT-PCR. H2O p the negative control. No amplification product is observed in patient
GM02525, who is homozygous for the D6432 deletion, which removes this portion of the gene. The cDNA of patient GM02533A was not
available.
Human Genome Mapping Project Resource Centre (Bor-
sani et al. 1998).
For sequence assembly and editing, we used both the
AutoAssembler version 1.4 (PE Biosystems) and the
DNA Strider 1.2 software programs (Marck 1988). Mul-
tiple sequence alignment (MSA) was performed by the
Clustal W algorithm (Thompson et al. 1994). ML4 nu-
cleotide and amino acid sequences were compared with
the Non-Redundant Sequences databases of the Na-
tional Center for Biotechnology Information, by BLAST
version 2.0 (Altschul et al. 1997). Protein sequence anal-
ysis was achieved by the PIX—Identity Unknown Pro-
tein Sequence tool available from the Human Genome
Mapping Project Resource Centre; in particular, the
prediction of transmembrane domains was performed
by the TMpred—Prediction of Transmembrane Regions
and Orientation program. The search against a Pro-
fileScan Server database was performed at ISREC-
Bioinformatics.
Immunofluorescence
For immunofluorescence studies, COS7 cells were
grown in 8-well slide culture chambers (Nunc) with Dul-
becco’s modified Eagle’s medium with 10% fetal calf
serum. The cDNA region containing the entire ML4
open reading frame (ORF) was amplified by PCR using
cloned Pfu polymerase (Stratagene) and 21977 IMAGE
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Figure 4 MSA using the Clustal W algorithm and hydropathy plot of the mucolipidin protein. a, MSA between mucolipidin and related
amino acid sequences found in protein databases. Mucolipidin p human mucolipidin polypeptide (545-amino-acid form); FLJ11006 p hy-
pothetical protein FLJ11006 (GenBank accession number BAA91951) predicted from a cDNA clone identified by a large-scale cDNA sequencing
approach; CG8743 (GenBank accession number AE003516) and CE25082 (GenBank accession number not available) p predicted proteins
from genomic sequences of Drosophila melanogaster and Caenorhabditis elegans, respectively. Identical residues (shaded) and conservatively
substituted residues (unshaded) are boxed. The gaps inserted by the Clustal W program are denoted by broken lines. b, Top, Hydropathy plot
of the mucolipidin protein (545-amino-acid form). The amino acid position is plotted as a function of the average hydrophobicity of an 11-
amino-acid peptide (Kyte and Doolittle 1982). The region corresponding to the TRPC-like profile is shown above the plot, as a thick diagonally
striped line. Bottom, MSA between a 136-amino-acid sequence of mucolipidin (amino acids 354–490, also indicated as a shaded box in the
hydropathy plot) and a region of human proteins belonging to the polycystic kidney disease 2 family. PKDREJ p polycystic kidney disease
and receptor for egg jelly (sea urchin homologue)–like protein (GenBank accession number NP_006062); PKD2L2p polycystic kidney disease
2–like 2 (GenBank accession number AAF65622); PKD2 p polycystic kidney disease 2 protein (GenBank accession number NP_032887);
PKD2L1p polycystic kidney disease 2–like 1 protein (GenBank accession number NP_057196). The first and last amino acids of each sequence,
numbered according to their database entries, are at the end of each sequence.
cDNA clone as template. The following sense and an-
tisense primers containing suitable restriction sites
were used to amplify the ML4 coding region: 129/BGL
(5′-ATAGATCTATGACACCTTCGCAGCCTACAC-3′)
and 129/ECO (5′-GGAATTCTCAATTCACCAGCA-
GCGAATG-3′), for cloning in pMHA vector, and
MY129ECO (5′-AGGAATTCATGACACCTTCGCAG-
CCTACAC-3′) and MY129SAL (5′-AAGTCGACAA-
TTCACCAGCAGCGAATG-3′), for cloning in pMT21
vector. 129-pMHA contains the amplified insert 5′ in-
frame with the hemagglutinin (HA) epitope within plas-
mid pMHA, whereas, in the case of the 129-pMT21
construct, the insert was 3′ in-frame with the Myc epi-
tope tag within the plasmid pMT21. Transfections were
performed overnight, with increasing amounts (0.5–
1.5 mg) of recombinant plasmid DNA for each well and
with LipofectAMINE reagent, according to the manu-
facturer’s guidelines (Life Technologies). Transfection
experiments using the same amount of vector DNA
(pMT21 and pMHA) were performed as a control.
COS7 cells were grown for an additional 48 h, were
rinsed with PBS, and then were fixed immediately with
4% (w/v) PBS-buffered paraformaldehyde. Cells were
subsequently permeabilized with 0.2% (v/v) Triton X-
100 and were blocked with 10% (v/v) porcine serum
and incubated, either with anti-HA monoclonal anti-
body (4 mg/ml) (Boehringer Mannheim) or with anti-
Myc monoclonal antibody, in PBS plus 5% (v/v) porcine
serum and 0.1% (v/v) Triton X-100. Staining was per-
formed after incubation with fluorescein 5–isothiocyan-
ated conjugated isotype-specific antibodies (1:150 dilu-
tion) (DAKO). Fluorescence microscopy was performed
by an Axioplan microscope equipped with an MC 100
Spot Device camera (Zeiss).
Expression Studies
Northern blot of poly(A) RNA from various human
adult tissues was purchased from Clontech and was hy-
bridized by means of standard protocols (Sambrook et
al. 1989). The cDNA insert of the human IMAGE clone
209402 (covering the 1,093–2,245 bp ML4 cDNA re-
gion) was used as a probe. Reverse transcriptase–PCR
(RT-PCR) experiments were performed according to the
manufacturer’s recommended conditions (Gibco BRL).
Mutation Analysis
Oligonucleotide primers for the amplification of all
the ML4 exons were designed in the intronic flanking
sequences and are available on request. For mutation
analysis, the following primers were used: D6432 mu-
tation, ZFP2F (5′-AAGCCCTGCATCCATGATG-3′)
and 129 6R (5′-CACATGAACCCCACAAACTCC-3′;
4862 ArG mutation at the genomic level, 1293F (5′-
CGGACTCACAGGCCCTCC-3′) and 1293R (5′-CCA-
ACAGTGAAGCCTCGTCC-3′); and 4862 ArG mu-
tation at the cDNA level, MC21B (5′-GAGCTGCT-
TTCCCAAAAGG-3′) and MC21E (5′-ACACCTTCG-
CAGCCTACAC-3′).
Haplotype Analysis
Fluorescence-labeled oligonucleotides for MLIV–
critical region polymorphic markers were designed on
the basis of sequences publicly available. PCR products
were detected by an Applied Biosystems ABI 377 fluo-
rescent sequencer and were analyzed by GENESCAN,
version 2.1 (Applied Biosystems).
Results
Identification of the ML4 Gene—and Mutation
Analysis in Patients with MLIV
To identify the gene responsible for MLIV, we ana-
lyzed the genomic sequences located within the MLIV
critical region (Slaugenhaupt et al. 1999). Thirty-two
chromosome 19 markers, including sequence-tagged
sites and short tandem repeats, were retrieved from
The Genetic Location Database and were used as queries
in the BLAST sequence-homology search against nucle-
otide-sequence databases. Using a set of bioinformatic
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Table 1
Mutation and Haplotype Analysis in Patients with MLIV
GENOTYPE
HAPLOTYPEb
(Core Markers)
D19S869 D19S873 D19S905 D19S884
Individual (status):a
WG987 (carrier) WT 275 116 216 238
D6432 275 126 234 222c
WG988 (carrier) WT 275 120 216 232
4862 ArG 283 120 216 230
WG909 (affected) D6432 275 126 234 222c
4862 ArG 283 120 216 230
GM02525 (affected) D6432 275 126 234 230
D6432 275 126 234 230
GM02526 (affected) D6432 275 126 234 230
4862 ArG 285c 120 216 230
GM02527 (affected) 4862 ArG 275c–283 120 216 230–236c
4862 ArG 120 216
GM02529 (affected) D6432 275 126 234 230
4862 ArG 283 120 216 230
GM02533A (affected) D6432 275 126 234 230
4862 ArG 283 120 216 230
Haplotype:
Major 4862 ArG 283 120 216 230
Minor D6432 275 126 234 230
a WG987 and WG988 are the unaffected parents of patient WG909; GM02529 and GM02533A
are brothers.
b The major and minor haplotypes are as reported by Slaugenhaupt (1999).
c Allele(s) for distal markers that differ from the major and minor haplotypes.
tools (see the Patients, Material, and Methods section),
we selected and analyzed 30 of either PAC or BAC se-
quences, which led us to the identification of a number
of putative novel genes.
One of the genes that we identified shares signifi-
cant sequence identity with polycystin-2, an integral
membrane protein encoded by the polycystic kidney dis-
ease 2 (PKD2) gene, which is mutated in one form of
autosomal dominant polycystic kidney disease (Cai et
al. 1999) (see below). On the basis of the data presented
in this article, we have named the gene “ML4.” ML4
maps to PAC RP11-492L14 (GenBank accession num-
ber AC021153) and BAC CTD-2207023 (GenBank ac-
cession number AC008878). These genomic clones con-
tain the sequences of the “core markers” D19S873,
D19S905, and D19S901, which are included within the
1.2-cM region defined by linkage disequilibrium (Slau-
genhaupt et al. 1999). ML4 is flanked by the gene for
FLJ10390 (GenBank accession number AK001252,
which is similar to the human zinc-finger protein 135
gene), and by the gene for neuropathy target esterase
(NTE [GenBank accession number AJ004832]).
A cDNA contig of 2,273 bp (GenBank accession
number AJ293659) was assembled by full-insert se-
quence analysis of IMAGE clones 209402, 21977, and
2517653, corresponding to expressed-sequence tags
(ESTs) of the transcript. This transcript contains an
ORF of 1,635 bp encoding a protein of 545 amino acids
(fig. 1a). The codon for the translation-initiator methi-
onine (Met-1), which does not fulfill the Kozak consen-
sus sequence (Kozak 1984), is preceded by several in-
frame stop codons. Sequence comparison of clones
21977 and 2517653, both from libraries of brain cDNA,
indicates that clone 2517653 represents a shorter (2,037
bp), alternatively spliced transcript missing a portion
(235 bp) of exon 5 (for ML4 gene structure, see below)
(fig. 1a). A corresponding alternatively spliced form has
been observed in ESTs from other species (data not
shown). Since the size of the spliced region is not an
exact multiple of 3, this alternative ML4 transcript pre-
sents a longer ORF (fig. 1a), with the first Met-1 (which
only marginally fulfills the Kozak consensus sequence)
located in exon 1 on a different frame.
The predicted protein product is 580 amino acids long
(GenBank accession number AJ293970) and, because of
the usage of the same reading frame in the two forms
downstream of the splicing event, is identical to the 545-
amino-acid form in the last 353 residues (fig. 1a). RT-
PCR analysis on RNA from several human tissues sug-
gests that the longer transcript, corresponding to clone
21977, is clearly the most abundant one (data not
shown).
Comparison of the ML4 cDNA sequence with the
sequences of genomic clones RP11-492L14 and CTD-
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Figure 5 Immunofluorescence of ML4 encoded protein. COS7 cells were transfected with either 129-pMHA (a) or 129-pMT21 (b)
constructs and were grown 48 h prior to fixation and immunofluorescence staining. Cells were fixed with paraformaldehyde and were per-
meabilized with Triton X-100 and then were treated with either anti-HA (A) or anti-Myc (B) monoclonal antibodies. Staining was performed
with fluorescein 5–isothiocyanated isotype-specific antibodies.
2207O23 revealed that the gene is organized into 13
exons spanning 11.3 kb. All the ML4 exon-intron junc-
tions agree with the GT-AG consensus sequence.
Northern blot analysis of poly(A) RNA, using aML4
cDNA probe from several human adult tissues, identified
a single 2.2-kb band present in all tissues tested, with
the exception of colon tissue and thymus tissue (fig. 1b).
The ML4 transcript can also be detected in fibroblast
cell lines, by RT-PCR (see below). These data support
an almost ubiquitous expression of the gene.
ML4 mutation analysis was performed in six patients
with MLIV who are from five different families. Fibro-
blast cell lines and genomic DNAs were obtained from
cell repositories (see the Patients, Material, and Methods
section). Biological samples from parents were available
for one patient only (WG909; see below).
Patient GM02525 is homozygous for a deletion re-
moving 6,432 bp (D6432), spanning a region from the
5′ end of the gene to exon 6 (fig. 2). The absence of
ML4 transcript from this patient’s fibroblasts was de-
tected by RT-PCR using primers designed from the se-
quence of exons 7–13 (data not shown). This result sug-
gests that the deletion encompassing 938 bp upstream
of the cDNA sequence removes ML4 transcription reg-
ulatory elements.
Patient GM02527 is either homozygous or hemizy-
gous for an ArG transition at position 2 of the AG
acceptor site of the intron flanking exon 4 (mutation
4862 ArG), which disrupts the GT-AG rule of splic-
ing. Consequently, the resulting transcript lacks 165 bp,
because of the skipping of exon 4 (fig. 3a). This causes
a frameshift leading to a premature translation termi-
nation 374 bp downstream. The predicted truncated
protein retains only the first 21 amino acids of the wild-
type protein. All the other patients, including WG909
GM02526, GM02529, and GM02533A (who is affected
brother of GM02529), were found to be compound het-
erozygotes for the aforementioned D6432 and 4862
ArG mutations (figs. 2c and 3c). As shown in figure 3b,
the 4862 ArG mutation segregates with the disease
in the family of patient WG909.
To test whether these two mutations represent the
“major” and “minor” founder mutations predicted by
haplotype studies of families with MLIV (Slaugenhaupt
et al. 1999), we performed haplotype analysis on our
patients, with four MLIV-CR polymorphic markers
(table 1). Of these markers, D19S873 and D19S905 rep-
resent two of the core markers described by Slaugen-
haupt et al. (1999). The allele phases could be unequiv-
ocally established only in patient WG909 (because of
the availability of the parents) and in GM02525 (be-
cause of the homozygosity for all the markers). In all
other patients who are compound heterozygotes, allele
phases were arbitrarily inferred to fit with the two most
common haplotypes. The major mutation in Ashkenazi
Jewish patients with MLIV clearly appears to be 4862
ArG, since it is associated with the founder allele
marked by the 283-120-216-230 haplotype correspond-
ing to markers D19S869, D19S873, D19S905, and
D19S884 (Slaugenhaupt et al. 1999) (table 1). The
D6432 mutation probably represents the minor founder
allele, since it is associated with a less frequent haplotype
(275-126-234-230) observed in the same population (ta-
ble 1). Therefore, the two mutations that we identified
are likely to account for 96% of the MLIV chromosomes
in the Ashkenazi Jewish population (Slaugenhaupt et al.
1999). In patients WG909, GM02526, and GM02527,
alleles for the distal markers (indicated by footnote “c”
in table 1) differ from those of the major and minor
haplotypes. Slaugenhaupt et al. (1999) have reported
similar discrepancies, which are probably due to ances-
tral recombination events, in patients with MLIV.
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Sequence Analysis and Cellular Localization of the
ML4 Gene Product
To understand the biochemical function of the ML4
gene product, we performed a sequence database search,
using the predicted protein sequence as a query. Signif-
icant homologies with three uncharacterized proteins
were identified, which were found to spread along most
of the length of the ML4 gene. The highest homology
was detected with the human protein FLJ11006 (61%
identity; 77% similarity), followed by the CG8743 pro-
tein from Drosophila melanogaster (44% identity; 64%
similarity) and the CE25082 Caenorhabditis elegans
polypeptide (40% identity; 63% similarity) (fig. 4a).
In addition to the homology with these proteins of
unknown function, the region spanning amino acids
354–490 of the ML4-encoded protein shows a lower
but significant identity with proteins belonging to PKD2
(fig. 4b). Interestingly, a search against a ProfileScan
Server database revealed a significant match for a tran-
sient receptor potential channel (TRPC)–like pattern
seen in a family of putative Ca2 channels (Zhu et al.
1996; Harteneck et al. 2000). The match is restricted to
the region spanning amino acids 296–486, which is
highly significant in channel function, since it includes
the region believed to constitute the ion pore (Zhu et al.
1996).
The TMpred membrane-spanning–prediction pro-
gram (TMpred—Prediction of Transmembrane Regions
and Orientation) revealed the presence of six putative
transmembrane domains in the C-terminal portion of
the ML4-encoded protein (fig. 4b). Of these, the fifth
domain, showing a lower score, is thought not to span
the membrane completely in TRPC proteins (Birnbaum-
er et al. 1996). These data suggest that ML4 encodes an
integral membrane protein. To provide experimental ev-
idence for this prediction, we performed immunohisto-
chemical analysis of COS7 cells transfected with recom-
binant ML4 cDNA (encoding for the 545-amino-acid
form) containing two different protein tags (HA and
Myc) adjacent to the ML4 sequence. The results show
a typical plasma-membrane localization (fig. 5), whereas
cells transfected with only the vector DNAs do not show
any staining (data not shown).
Discussion
The severity of the mutations found, as well as their
concordance with both disease status and haplotype
data, clearly indicate that we have identified the MLIV
gene and the two major mutations causing this disorder.
Therefore, MLIV is caused by a loss of function of the
ML4 gene product, which we therefore have named
“mucolipidin.” We have demonstrated that mucolipidin
is an integral membrane protein ubiquitously found in
almost all tissues tested. Hypotheses about the biological
role of mucolipidin may emerge not only from studies
of the cellular phenotype observed in MLIV but also
from the similarities detected between mucolipidin and
other known proteins. Studies performed in MLIV cells
strongly suggest that mucolipidin plays a role in trans-
port and/or sorting in the late endocytic pathway. In this
context, the presence, within mucolipidin, of a protein
profile described in molecules involved in Ca2 transport
(i.e., TRPC [Putney and McKay 1999]) is intriguing.
Intracellular Ca2 levels are of crucial importance in a
variety of biological processes, some of which appear to
be altered in MLIV; for example, intraorganellar Ca2
is required for the fusion of late endosomes and lyso-
somes, the reformation of lysosomes, and the dynamic
equilibrium of organelles in the late endocytic pathway
(Pryor et al. 2000). In addition, localized Ca2 levels
determine the spatial and temporal targeting of protein
kinase C alpha (PKC alpha) inside the cell (Maasch et
al. 2000). Interestingly, phorbol myristate acetate–
mediated translocation of PKC from the cytosolic to the
membranous compartment is perturbed in MLIV fibro-
blasts (Turgeman and Boneh 1996).
Mucolipidin also shares significant similarities with
polycystin-2, the product of the PKD2 gene involved in
autosomal dominant polycystic kidney disease (ADPKD
[MIM 173910]). Polycystin-2 is also predicted to be an
integral membrane protein, with six membrane-span-
ning domains and intracellular NH2 and COOH ter-
mini. Similar to what is seen in mucolipidin, a TRPC
domain is present also in polycystin-2. An analysis of
membrane transport revealed that basolateral traffick-
ing of proteins and lipids is impaired in polarized
ADPKD cells (Charron et al. 2000).
Together, the presence of a TRPC-like domain, the
homology with PKD2-like proteins, and the localization
to the plasma membrane suggest that mucolipidin me-
diates membrane trafficking of proteins and lipids. The
possibility that mucolipidin participates in intracellular
calcium-level regulation, by acting as an ion channel,
needs to be further explored by detailed studies. With
the cloning of the ML4 gene encoding mucolipidin,
functional studies performed in both wild-type and
MLIV cells are now feasible. These will not only ad-
vance our knowledge of the pathogenesis of this severe
disease but also will help to elucidate a fundamental
process in cell biology, such as endocytosis.
Note added in proof.—After the manuscript of this
article was submitted for publication, an article (Bargal
et al. 2000) was published describing both the cloning
of a gene identical to ML4 and the identification of mu-
tations in MLIV.
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